Skip to main content
Clinical Trials/NCT00726921
NCT00726921
Completed
Not Applicable

Detection of Significant Coronary Artery Disease in Nephropathy Patients Utilizing Coronary CTA and Real Time Perfusion DSE: Comparison With Quantitative Coronary Angiography and Patient Outcome

University of Nebraska1 site in 1 country189 target enrollmentAugust 25, 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
University of Nebraska
Enrollment
189
Locations
1
Primary Endpoint
Detect coronary artery disease (CAD) by invasive angiography in end-stage renal disease (ESRD) patients
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This study investigates hypothesizes that the combination of dobutamine stress echocardiography with dobutamine stress echocardiography with real time perfusion myocardial contrast echocardiography and coronary computed tomography is a better modality for detecting coronary artery disease in end-stage renal disease patients than coronary angiography, and in predicting patient outcomes. Demonstrating this would lead to increased use of DSE with RTCE and coronary CT at kidney transplant centers throughout the nation, leading to improved anatomical and functional detection of CAD without the need for further invasive procedures.

Detailed Description

Primary: To examine the ability of dobutamine stress dobutamine stress echocardiography with real time perfusion (DSE with RTCE) and coronary computed tomographic angiography (cCTA) to detect anatomically significant coronary artery disease (CAD) as defined by quantitative coronary angiography in end-stage renal disease (ESRD) patients Secondary: To identify which of these tests is most predictive of patient outcomes. This will be a pilot study enrolling 75 participants. This is based off obtaining 80% power and a 90% rectangular confidence region for sensitivity and specificity using one-sided confidence limits, this corresponds to two 95% univariate confidence intervals (one for sensitivity and one for specificity). With 73 patients screened in total there will be 80% power to form a 90% rectangular confidence region around 90% sensitivity and 90% specificity, excluding sensitivities less than 69% and specificities less than 73%. We believe the sensitivities and specificities of both DSE with RTCE and cCTA will be within these confidence regions.

Registry
clinicaltrials.gov
Start Date
August 25, 2008
End Date
December 21, 2012
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diabetes mellitus
  • Patients undergoing kidney transplant evaluation.
  • Currently on hemodialysis
  • Adults 19-65 years of age
  • Written informed consent from a participant who is deemed medically competent by principal investigator, secondary investigators, or participating personnel as written in II.26 (b)
  • Male or female

Exclusion Criteria

  • Previous history of percutaneous coronary intervention
  • Coronary artery bypass surgery
  • Prior myocardial infarction or AMI (troponin greater than 1.0) within 48 hours of the test
  • Atrial or ventricular arrhythmias that cannot be controlled to heart rates \<65 beats per minute
  • Known allergy to iodinated contrast
  • Decompensated Congestive Heart failure
  • Acute respiratory failure as manifested by signs and symptoms of carbon dioxide retention or hypoxemia
  • Pregnant (based on history/information obtained from the patient)
  • Possibility that potential subject may be pregnant (based on history/information obtained from the patient)

Outcomes

Primary Outcomes

Detect coronary artery disease (CAD) by invasive angiography in end-stage renal disease (ESRD) patients

Time Frame: One year

To examine the ability of dobutamine stress echocardiography with real time perfusion (DSE with RTCE) and coronary computed tomographic angiography (cCTA) to detect anatomically significant coronary artery disease (CAD) as defined by invasive angiography in end-stage renal disease (ESRD) patients

Secondary Outcomes

  • Predictive Test(3 years)

Study Sites (1)

Loading locations...

Similar Trials